Investments in pharmaceuticals before and after TRIPS

Review of Economics and Statistics

Volumn 94, Issue 4, 2012, Pages 1157-1172

  Kyle, Margaret K ^a   McGahan, Anita M ^b,c  

^a TOULOUSE SCHOOL OF ECONOMICS   (France)

^b UNIVERSITY OF TORONTO   (Canada)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886746949     PISSN: 00346535     EISSN: 15309142     Source Type: Journal    
DOI: 10.1162/REST_a_00214     Document Type: Article

References (39)

1. Acemoglu, D., and J. Linn, "Market Size in Innovation: Theory and Evi-dence from the Pharmaceutical Industry,"Quarterly Journal of Economics 119 (2004), 1049-1090.
2. Arora, A., A. Fosfuri, and A. Gambardella, Markets for Technology: The Economics of Innovation and Corporate Strategy (Cambridge, MA: MIT Press, 2001).
3. Arora, A., and A. Gambardella, "Ideas for Rent: An Overview of Markets for Technology,"Industrial and Corporate Change 19 (2010), 775-803.
4. Burk, D. A., and M. A. Lemley, The Patent Crisis and How the Courts Can Solve It (Chicago: University of Chicago Press, 2009).
5. Chaudhuri, S., P. Goldberg, and P. Jia, "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinilones in India,"American Economic Review 96 (2006), 1477-1514.
6. Cohen, J. C., "Expanding Drug Access in Brazil: Lessons for Latin Amer-ica and Canada,"Canadian Journal of Public Health 97 (2006), 115-118.
7. Cohen, J. C., and P. Illingworth, "The Dilemma of Intellectual Property Rights for Pharmaceuticals: The Tension between Insuring Access of the Poor to Medicines and Committing to International Agree-ments,"Developing World Bioethics 3 (2003), 27-48.
8. Cohen, W., and F. Malerba, "Is the Tendency to Variation a Chief Cause of Progress?"Industry and Corporate Change 10 (2001), 587-608.
9. Cohen, W., R. Nelson, and J.Walsh, "Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not),"NBER working paper no. 7552 (2000).
10. Correa, C., "Review of the TRIPS Agreement: Fostering the Transfer of Technology to Developing Countries"(Penang, Malaysia: Third World Network, 2001).
11. Danzon, P., and A. Towse, "Differential Pricing for Pharmaceuticals: Reconciling Access, K & D, and Patents,"Journal of Health Care Financing and Economics 3 (2003), 183-205.
12. DiMasi, J., H. Grabowski, and J. Vernon, "R&D Costs and Returns by Therapeutic Category,"Drug Information Journal 38 (2004), 211-223.
13. DiMasi, J., R. Hansen, and H. Grabowski, "Reply: Setting the Record Straight on Setting the Record Straight: Response to the Light and Warburton Rejoinder,"Journal of Health Economics 24 (2005), 1049-1053.
14. Dubois, P., O. Mouton, F. Scott Morton, and P. Seabright, "Market Size and Pharmaceutical Innovation,"CEPR discussion paper no. DP8367 (2011).
15. Finkelstein, A., "Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry,"Quarterly Journal of Economics 119 (2004), 527-564.
16. Gambardella, A., and A. McGahan, "Business-Model Innovation: Gen-eral Purpose Technologies and Their Implications for Industry Structure,"Long Range Planning 43 (2010), 262-271.
17. Ginarte, J., and W. Park, "Determinants of Patent Rights: A Cross-National Study,"Research Policy 26 (1997), pp. 283-301.
18. Grabowski, H., "Patents, Innovation and Access to New Pharmaceuti-cals,"Journal of International Economic Law 5 (2002), 849-860.
19. Hamdan-Livramento, I. M., "How Compliant Are Developing Countries with Their TRIPS Obligations?"CEMI working paper no. 2009-2001 (2009).
20. Kitch, E. W., "The Nature and Function of the Patent System,"Journal of Law and Economics 20 (1977), 265-290.
21. Kortum, S., and J. Lerner, "Stronger Protection or Technological Revolu-tion: What Is Behind the Recent Surge in Patenting?"Carnegie-Rochester Conference Series on Public Policy 48 (1998), 247-304.
22. Kremer, M., "Pharmaceuticals and the Developing World,"Journal of Economic Perspectives 16 (2002), 67-90.
23. Lanjouw, J., "Intellectual Property and the Availability of Pharmaceuti-cals in Poor Countries,"Innovation Policy and the Economy,3 (2003), 91-129.
24. Lanjouw, J., and I. Cockburn, "New Pills for Poor People? Empirical Evi-dence after GATT,"World Development 29 (2001), 265-289.
25. Li, X., "The Impact of Higher Standards in Patent Protection for Pharma-ceutical Industries under the TRIPS Agreement: A Comparative Study of China and India,"World Economy 31 (2008), 1367-1382.
26. Lichtenberg, F., and J. Waldfogel, "Does Misery Love Company? Evi-dence from Pharmaceutical Markets before and after the Orphan Drug Act,"NBER working paper no. 9750 (2003).
27. Maskus, K., "Parallel Imports in Pharmaceuticals: Implications for Com-petition and Prices in Developing Countries,"report to the World Trade Organization (2001).
28. Merges, R. P., & R. R. Nelson, "On Limiting or Encouraging Rivalry in Technical Progress: The Effect of Patent Scope Decisions,"Jour-nal of Economic Behavior and Organization 25 (1994), 1-24.
29. Moran, M., J. Guzman, A.-L. Ropars, A. McDonald, and N. Jameson, "Neglected Disease Research and Development: How Much Are We Really Spending?"PLoS Med 6 (2009), e1000030. doi:10.1371 /journal.pmed.1000030.
30. Outterson, K., "Disease Based Limitations on Compulsory Licenses under Articles 31 and 31BIS,"Boston University School of Law working paper no. 09-26 (2009).
31. Oliveira, M. A., J. A. Z. Bermudez, G. C. Chaves, and G. Velásquez, "Has the Implementation of the TRIPS Agreement in Latin Amer-ica and the Caribbean Produced Intellectual Property Legislation That Favours Public Health?"Bulletin of the World Health Orga-nization 82 (2004), 815-821.
32. "Pressure Rises on Producer of Flu Drug,"New York Times, October 11, 2005
33. Qian, Y., "Do National Patent Laws Stimulate Domestic Innovation in a Global Patenting Environment? A Cross-Country Analysis of Pharmaceutical Patent Protection, 1978-2002,"this REVIEW 89 (2007), 436-453.
34. Sakakibara, M., and L. Branstetter, "Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patents Law Reforms,"RAND Journal of Economics 32 (2001), 77-100.
35. Rubin, D. B., Multiple Imputation for Nonresponse in Surveys (New York: Wiley, 1987).
36. Taubman, A., "Rethinking TRIPS: 'Adequate Remuneration' for Non-Voluntary Patent Licensing,"Journal of International Economic Law 11 (2008), 927-970.
37. Ward, M., and D. Dranove, "The Vertical Chain of Research and Devel-opment in the Pharmaceutical Industry,"Economic Inquiry 33 (1995), 70-87.
38. Westerhaus, M., and A. Castro, "How Do Intellectual Property Law and International Trade Agreements Affect Access to Antiretroviral Therapy?"PLoS Medicine 3 (2006), 1230-1236.
39. World Trade Organization, "TRIPS and Pharmaceutical Patents Fact Sheet"(2006). http://www.wto.org/english/tratop_e/trips_e/trips factsheet_pharma_2006_e.pdf.